|
|
Trovan (Alatrofloxacin) I.V.
|
 |
Systemic anti-infective
|
 |
Antibiotic
|
 |
Serious bacterial infections requiring therapy in in-patient health care facilities (hospital-, community-acquired Pneumonia, complicated intra-abdominal infections, gynecologic and pelvic infections, complicated Skin Infections such as diabetic foot infections)
|
 |
Adults and teens over 18: for treatment of bacterial infections: 200 to 300 mg injected slowly into a vein over a period of sixty minutes once every 24-hours for up to 14 days, depending on the site and type of infection. For prevention of infection in surgical patients: Adults and teens over 18: 200 mg injected slowly into a vein over a period of sixty minutes, one-half to four hours before surgery.
|
 |
Category C
|
 |
Diarrhea, dizziness, lightheadedness, headache, vaginal Yeast Infection, vomiting, photosensitivity, liver toxicity, severe allergic reactions
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
 |
|
|
